Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel

  • Lyn Guenther
  • Richard G. Langley
  • Neil H. Shear
  • Robert Bissonnette
  • Vincent Ho
  • Charles Lynde
  • Eileen Murray
  • Kim Papp
  • Yves Poulin
  • Catherine Zip
Article

Abstract

Background

Approximately 2% of people worldwide have psoriasis, with as many as 1 million people with psoriasis in Canada alone.1,2 The severity of psoriasis ranges from mild to severe. It can lead to substantial morbidity and psychological stress and have a profound negative impact on patient quality of life.3,4 Although available therapies reduce therapies reduce the extent and severity of the disease and improve quality of life,3 reports have indicated a patient preference for more aggressive therapy and a dissatisfaction with the effectiveness of current treatment options.5

Objective

A Canadian Expert Panel, comprising Canadian dermatologists, convened in Toronto on 27 February 2004 to reach a consensus on unmet needs of patients treated with current therapies and how to include the pending biologic agents in and improve the current treatment algorithm for moderate-to-severe psoriasis. Current treatment recommendations suggest a stepwise strategy starting with topical agents followed by phototherapy and then systemic agents.3,6,7 The Panel evaluated the appropriate positioning of the biologic agents, once approved by Health Canada, for the treatment of moderate-to-severe psoriasis.

Methods

The Panel reviewed available evidence and quality of these data on current therapies and from randomized, controlled clinical trials.8, 9, 10, 11, 12, 13, 14 Subsequently, consensus was achieved by small-group workshops followed by plenary discussion.

Results

The Panel determined that biologic agents are an important addition to therapies currently available for moderate-to-severe psoriasis and proposed an alternative treatment algorithm to the current step wise paradigm.

Conclusion

The Panel recommended a new treatment algorithm for moderate-to-severe psoriasis whereby all appropriate treatment options, including biologic agents, are considered together and patients’ specific characteristics and needs are taken into account when selecting the most appropriate treatment option.

Sommaire

Antècèdents

Près de 2 % de la population mondiale est atteinte de psoriasis, dont un million de personnes au Canada.1,2 Le psoriasis peut varier de bénin à grave. Cette affection entraîne arfois une morbidité accrue et une détresse psychologique en plus d’avoir un impact négatif profond’sur la qualité de vie du patient.3,4 Bien que les traitements disponibles réduisent I’étendue et la gravité de la maladie et améliorent la qualité de vie,3 les rapports ont dénoté une préférence pour les traitements plus agressifs et une insatisfaction à I’égard de I’efficacite des options de traitement actuelles.5

Objectif

Un panel d’experts canadiens, formé de dermatologues, s’est réuni á Toronto le 27 février 2004 en vue d’atteindre un consensus sur les besoins non comblés des patients traités au moyen des thérapies actuelles, ainsi que d’évaluer les façons d’inclure les agents biologiques et d’améliorer les algorithmes de traitement du psoriasis modéré à grave. Actuellement, les traitements recommandés sont axés sur une stratégic par étapes, débutant avec des agents topiques, suivis d’une phototherapie et enfin des agents systémiques.3,6,7 panel a évalué le positionnement approprié des agents biologiques, une fois approuvés par Santé Canada, dans le traitement du psoriasis modéré à grave.

Méthodes

Le panel a passé en revue les rapports disponibles et la qualite des données relativement à ces thérapies ainsi que ceux des essais cliniques randomisés.8, 9, 10, 11, 12, 13, 14 Par la suite, un consensus a été atteint au moyen de petits ateliers de travail suivis d’une discussion plénière.

Résultats

Le panel a déterminé que les agents biologiques étaient un important ajout aux options thérapeutiques offertes actuellement dans le traitement du psoriasis modéré à grave et a proposé un algorithme de traitement en replacement à I’algorithme par étapes actuel.

Conclusion

Le panel a recommandé un nouvel algorithme de traitement pour le psoriasis modéré à grave, où on considère toutes les options thérapeutiques, y compris les agents biologiques, dans leur ensemble et on tient compte des caractéristiques et des besoins specifiques de chaque patient dans le choix de I’option adéquate.

References

  1. 1.
    Christophers, E 2001Psoriasis—epidemiology and clinical spectrumClin Exp Dermatol26314320CrossRefPubMedGoogle Scholar
  2. 2.
    Nail, L, Gulliver, W, Charmley, P,  et al. 1999Search for the psoriasis susceptibility gene: the Newfoundland StudyCutis 64323329Google Scholar
  3. 3.
    Ashcroft, DM, Li Wan Po, A, Griffiths, CE 2000Therapeutic strategies for psoriasisJ Clin Pharm Ther25110CrossRefPubMedGoogle Scholar
  4. 4.
    Choi, J, Koo, JY 2003Quality of life issues in psoriasisJ Am Acad Dermatol49S57S61CrossRefPubMedGoogle Scholar
  5. 5.
    Krueger, G, Koo, J, Lebwohl, M,  et al. 2001The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol137280284PubMedGoogle Scholar
  6. 6.
    Lebwohl M, Menter A, Koo J, et al. Psoriasis: Treatment options and patient management Ed. Portland, OR: National Psoriasis Foundation, 2002, pp 30–31 Physician Patient guide The algorithm cited is available @ http://www.psoriasis.org/files/pdfs/press/algorithm.pdf
  7. 7.
    Travis, L, Weinberg, JM 2002Medical backgrounder: psoriasisDrugs Today (Barc)38847865CrossRefGoogle Scholar
  8. 8.
    Leonardi, CL, Powers, JL, Matheson, RT,  et al. 2003Etanercept as monotherapy in patients with psoriasisN Engl J Med34920142022CrossRefPubMedGoogle Scholar
  9. 9.
    Krueger, GG, Papp, KA, Stough, DB,  et al. 2002A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol47821833CrossRefPubMedGoogle Scholar
  10. 10.
    Gottlieb, AB, Chaudhari, U, Mulcahy, LD,  et al. 2003Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasisJ Am Acad Dermatol48829835CrossRefPubMedGoogle Scholar
  11. 11.
    Chaudhari, U, Romano, P, Mulcahy, LD,  et al. 2001Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialLancet35718421847CrossRefPubMedGoogle Scholar
  12. 12.
    Lebwohl, M, Tyring, SK, Hamilton, TK,  et al. 2003A novel targeted T-cell modulator, efalizumab, for plaque psoriasisN Engl J Med34920042013CrossRefPubMedGoogle Scholar
  13. 13.
    Gordon, KB, Papp, KA, Hamilton, TK,  et al. 2003Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialJAMA29030733080PubMedGoogle Scholar
  14. 14.
    Ortonne, JP 2003Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasisJ Eur Acad Dermatol Venereol171216CrossRefPubMedGoogle Scholar
  15. 15.
    Tan, MH, Lebwohl, M 1998PsoriasisDrugs Today (Barc)34641647CrossRefGoogle Scholar
  16. 16.
    Brandrup, F, Green, A 1981The prevalence of psoriasis in DenmarkActa Derm Venereol61344346PubMedGoogle Scholar
  17. 17.
    Henseler, T, Christophers, E 1985Psoriasis of early and late onset: characterization of two types of psoriasis vulgarisJ Am Acad Dermatol13450456PubMedCrossRefGoogle Scholar
  18. 18.
    Whittam, LR, McGibbon, DH 1998The management of psoriasisInt J Clin Pract52487491PubMedGoogle Scholar
  19. 19.
    Callen, JP, Krueger, GG, Lebwohl, M,  et al. 2003AAD consensus statement on psoriasis therapiesJ Am Acad Dermatol49897899CrossRefPubMedGoogle Scholar
  20. 20.
    Krueger, GG, Feldman, SR, Camisa, C,  et al. 2000Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?J Am Acad Dermatol43281285CrossRefPubMedGoogle Scholar
  21. 21.
    Feldman, SR 2004A quantitative definition of severe psoriasis for use in clinical trialsJ Dermatolog Treat152729CrossRefPubMedGoogle Scholar
  22. 22.
    National Psoriasis Foundation. Facts: Psoriasis. http://www.psoriasis.org/facts/psoriasis/.2004
  23. 23.
    Lebwohl, M, Ali, S 2001Treatment of psoriasis. Part 1 . Topical therapy and phototherapyJ Am Acad Dermatol45487498quiz 499–502CrossRefPubMedGoogle Scholar
  24. 24.
    Lebwohl, M, Ali, S 2001Treatment of psoriasis. Part 2. Systemic therapiesJ Am Acad Dermatol45649661quiz 662–664PubMedGoogle Scholar
  25. 25.
    Gower, WR,Jr 1993Mechanism of glucocorticoid actionJ Fla Med Assoc80697700PubMedGoogle Scholar
  26. 26.
    Foster, RH, Broaden, RN, Benfield, P 1998TazaroteneDrugs55705711discussion 712PubMedGoogle Scholar
  27. 27.
    Muller, K 2000Current status and recent developments in anthracenone antipsoriaticsCurr Pharm Des6901918CrossRefPubMedGoogle Scholar
  28. 28.
    Pardasani, AG, Feldman, SR, Clark, AR 2000Treatment of psoriasis: an algorithm-based approach for primary care physiciansAm Fam Physician61725733, 736PubMedGoogle Scholar
  29. 29.
    Camisa C, ed. UVB phototherapy and coal tar. In: Chapter 12, Camisa, C (ed.), Psoriasis, Boston, Blackwell Scientific, 1994, pp 205–226Google Scholar
  30. 30.
    Gawkrodger, D on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists1997Current management of psoriasisJ Dermatology Treat82755CrossRefGoogle Scholar
  31. 31.
    Krutmann, J 1998Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapyJ Photochem Photobiol B44159164CrossRefPubMedGoogle Scholar
  32. 32.
    Melski, JW, Tanenbaum, L, Parrish, JA,  et al. 1977Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trialJ Invest Dermatol68328335CrossRefPubMedGoogle Scholar
  33. 33.
    Griffiths, CE, Clark, CM, Chalmers, RJ,  et al. 2000A systematic review of treatments for severe psoriasisHealth Technol Assess41125PubMedGoogle Scholar
  34. 34.
    Gordon, PM, Diffey, BL, Matthews, JN,  et al. 1999A randomized comparison of narrowband TL-01 phototherapy and PUVA photochemotherapy for psoriasisJ Am Acad Dermatol41728732PubMedGoogle Scholar
  35. 35.
    Honigsmann, H 2001Phototherapy for psoriasisClin Exp Dermatol26343350CrossRefPubMedGoogle Scholar
  36. 36.
    Koo, J, Lee, E, Lee, CS,  et al. 2004PsoriasisJ Am Acad Dermatol50613622CrossRefPubMedGoogle Scholar
  37. 37.
    Ramsay, CA, Schwartz, BE, Lowson, D,  et al. 2000Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study GroupDermatology2001724CrossRefPubMedGoogle Scholar
  38. 38.
    Margolis, D, Bilker, W, Hennessy, S,  et al. 2001The risk of malignancy associated with psoriasisArch Dermatol137778789PubMedGoogle Scholar
  39. 39.
    Compendium of pharmaceuticals and specialties. Ed. Ottawa: Canadian Pharmacists’ Associatin, 2004Google Scholar
  40. 40.
    Roenigk, HH,Jr, Auerbach, R, Maibach, H,  et al. 1998Methotrexate in psoriasis: consensus conferenceJ Am Acad Dermatol38478485PubMedGoogle Scholar
  41. 41.
    Heydendael, VM, Spuls, PI, Opmeer, BC,  et al. 2003Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasisN Engl J Med349658665CrossRefPubMedGoogle Scholar
  42. 42.
    Callis KP, Chadha A, Vaishnaw AK, et al. Reduction of CD45RP+ Effector T lymphocytes is not observed in the treatment of psoriasis with methotrexate. Presented at 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, CA, poster abstract 220. May 15–18, 2002Google Scholar
  43. 43.
    Ho, VC, Griffiths, CE, Berth–Jones, J,  et al. 2001Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort studyJ Am Acad Dermatol44643651PubMedGoogle Scholar
  44. 44.
    Shupack, J, Abel, E, Bauer, E,  et al. 1997Cyclosporine as maintenance therapy in patients with severe psoriasisJ Am Acad Dermatol36423432PubMedGoogle Scholar
  45. 45.
    Roenigk, HH,Jr 1999Acitretih combination therapyJ Am Acad Dermatol41S18S21PubMedGoogle Scholar
  46. 46.
    Lebwohl, M, Christophers, E, Langley, R,  et al. 2003An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol139719727CrossRefPubMedGoogle Scholar
  47. 47.
    Linden, KG, Weinstein, GD 1999Psoriasis: current perspectives with an emphasis on treatmentAm J Med107595605CrossRefPubMedGoogle Scholar
  48. 48.
    Koo, J, Lebwohl, M 1999Duration of remission of psoriasis therapiesJ Am Acad Dermatol415159PubMedGoogle Scholar
  49. 49.
    Boerbooms, AM, Kerstens, PJ, Loenhout, JW,  et al. 1995Infections during low-dose methotrexate treatment in rheumatoid arthritisSemin Arthritis Rheum24411421CrossRefPubMedGoogle Scholar
  50. 50.
    Lebwohl, M, Menter, A, Koo, J,  et al. 2004Combination therapy to treat moderate to severe psoriasisJ Am Acad Dermatol50416430PubMedGoogle Scholar
  51. 51.
    Weinstein, GD, White, GM 1993An approach to the treatment of moderate to severe psoriasis with rotational therapyJ Am Acad Dermatol28454459PubMedGoogle Scholar
  52. 52.
    Koo, J 1999Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic resultsJ Am Acad Dermatol41S25S28PubMedGoogle Scholar
  53. 53.
    Kerkhof, PC 1998The management of psoriasisNeth J Med524045CrossRefPubMedGoogle Scholar
  54. 54.
    Rapp, SR, Feldman, SR, Exum, ML,  et al. 1999Psoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol41401407PubMedGoogle Scholar
  55. 55.
    Naldi, L, Svensson, A, Diepgen, T,  et al. 2003Randomized clinical trials for psoriasis 1977–2000: the EDEN surveyJ Invest Dermatol120738741CrossRefPubMedGoogle Scholar
  56. 56.
    Krueger, JG 2002The immunologic basis for the treatment of psoriasis with new biologic agentsJ Am Acad Dermatol46123quiz 26PubMedGoogle Scholar
  57. 57.
    Gordon K, Pariser D, Langley R, et al. Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials. Presented at 62nd Annual Meeting of the American Acadamy of Dermatology, 6–11 February 2004, Washington, DC, poster 4Google Scholar
  58. 58.
    Leonardi CI, Goffe B, Sobell J, et al. The safety of efalizumab in patients with moderate to severe plaque psoriasis: Summary of clinical trial experience. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 613Google Scholar
  59. 59.
    Remicade® (infliximab), US prescribing information, 2003. Manufactured by Centocor, Inc.Google Scholar
  60. 60.
    Raptiva® (efalizumab), US prescribing information, 2004, http://www.raptiva.com Manufactured by Genentech, Inc.
  61. 61.
    Enbrel® (etanercept), US prescribing information, 2004, http://www.enbrel.comManufactured by Biogen, Idec, Inc.
  62. 62.
    Amevieve® (alefacept), US prescribing information, 2004, http://www.amevive.com
  63. 63.
    Cather, JC, Abramovits, W 2003Investigational therapies for psoriasisJ Am Acad Dermatol49S133S138CrossRefPubMedGoogle Scholar
  64. 64.
    Singri, P, West, DP, Gordon, KB 2002Biologic therapy for psoriasis: the new therapeutic frontierArch Dermatol138657663CrossRefPubMedGoogle Scholar
  65. 65.
    Gordon, KB, McCormick, TS 2003Evolution of biologic therapies for the treatment of psoriasisSkinmed2286294PubMedGoogle Scholar
  66. 66.
    Gottlieb AB, Evans R, Li S, et al. The efficacy of infliximab across a variety of subgroups with plaque psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 615Google Scholar
  67. 67.
    Gordon, KB, Vaishnaw, AK, O’Gorman, J,  et al. 2003Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsArch Dermatol13915631570CrossRefPubMedGoogle Scholar
  68. 68.
    Menter A, Gather JC. Long-term use of intravenous alefacept: Safety and off-treatment responses in patients who have received four or more courses of therapy. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 588Google Scholar
  69. 69.
    Ellis, CN, Mordin, MM, Adler, EY 2003Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trialAm J Clin Dermatol4131139PubMedGoogle Scholar
  70. 70.
    Gottlieb AB, Gordon KB, Caro I, et al. Long-term efalizumab therapy safely maintains psoriasis area and severity index improvement: Preliminary results from an open-label trial. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 611Google Scholar
  71. 71.
    Menter A, Toth D, Glazer S, et al. Efficacy and safety of 24-week continuous efalizumab therapy in patients with moderate to severe plaque psoriasis. Presented at Summer Academy 2003 of the American Academy of Dermatology, 25–29 July 2003, Chicago, IL, poster 44Google Scholar
  72. 72.
    Menter A, Hamilton T, Caro I, et al. Impact of efalizumab on patient-reported outcomes in patients with chronic moderate to severe plaque psoriasis: pooled results from three randomized phase III trials. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 608Google Scholar
  73. 73.
    Stone S, Papp KA, Caro I, et al. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 610Google Scholar
  74. 74.
    Leonardi CL, Elewski B, Camisa C, et al. The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 568Google Scholar
  75. 75.
    Krueger GG, Lebwohl M, Wang A, et al. Continuance on etanercept after early incomplete response in patients with psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 546Google Scholar
  76. 76.
    Elewski BE, Boh E, Papp K, et al. Efficacy and safety of etanercept in patients with psoriasis: Results of a global phase III study. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 618Google Scholar
  77. 77.
    Ogilvie A, Antoni C, Kavanaugh A, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): Substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Presented at 96th International Psoriasis Symposium, 18–22 June 2003, New York, NY, poster 8Google Scholar
  78. 78.
    Feldman SR, Bala M, Menter A, et al. The quality of life of patients with severe psoriasis treated with infliximab. Presented at 62nd Annual Meeting of the American Academy of Dermatology, February 6–11 2004, Washington, DC, poster 7Google Scholar
  79. 79.
    Guidelines of care for psoriasis. Committee on Guidelines of Care.1993Task Force on PsoriasisJ Am Acad Dermatol28632637CrossRefGoogle Scholar
  80. 80.
    Lebwohl, M 2003Combining the new biologic agents with our current psoriasis armamentariumJ Am Acad Dermatol49S118S124CrossRefPubMedGoogle Scholar
  81. 81.
    Kostovic, K, Nola, I 2002Phototherapy (UVB) and photochemotherapy (PUVA) for psoriasisActa Clin Croat41103112Google Scholar
  82. 82.
    8-Mop®capsules (methoxsalen capsules, USP, 10 mg), US prescribing information, 2003 ICN Pharmaceutical Inc.Google Scholar
  83. 83.
    Brown, SL, Greene, MH, Gershon, SK,  et al. 2002Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug AdministrationArthritis Rheum4631513158PubMedGoogle Scholar
  84. 84.
    The Lenercept Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group.1999TNF neutralization in MS: results of a randomized placebo-controlled multicenter studyNeurology53457465Google Scholar
  85. 85.
    Klareskog, L, Heijde, D, Jager, JP,  et al. 2004Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet363675681CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Lyn Guenther
    • 1
    • 2
  • Richard G. Langley
    • 3
  • Neil H. Shear
    • 4
    • 5
  • Robert Bissonnette
    • 6
  • Vincent Ho
    • 7
  • Charles Lynde
    • 8
    • 9
  • Eileen Murray
    • 10
    • 11
  • Kim Papp
    • 12
  • Yves Poulin
    • 13
    • 14
  • Catherine Zip
    • 15
    • 16
  1. 1.Department of DermatologyUniversity of Western OntarioLondonCanada
  2. 2.The Guenther Dermatology Research CentreLondonCanada
  3. 3.Division of Dermatogy, Department of MedicineDalhousie University and Queen Elizabeth II Health Science CentreHalifaxCanada
  4. 4.Division of Dermatology, Department of MedicineSunnybrook and Women’s College Health Science Centre, University of Toronto Medical SchoolTorontoCanada
  5. 5.Ventana Clinical Research CorporationTorontoCanada
  6. 6.Innovaderm Research Inc.MontrealCanada
  7. 7.Department of DermatologyUniversity of British ColumbiaVancouverCanada
  8. 8.University Health Network, University of TorontoTorontoCanada
  9. 9.Lynde Centre for DermatologyMarkhamCanada
  10. 10.Department of DermatologyUniversity of ManitobaWinnipegCanada
  11. 11.Winnipeg ClinicWinnipegCanada
  12. 12.Probity Medical ResearchWaterlooCanada
  13. 13.Department of DermatologyLaval UniversitySainte FoyCanada
  14. 14.Centre DermatologiqueSainte FoyCanada
  15. 15.Department of DermatologyUniversity of CalgaryCalgaryCanada
  16. 16.The Dermatology CentreCalgaryCanada

Personalised recommendations